Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PPIA | P62937 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29162756 | 0.86 | HTT (0.63) | HTTMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL28082064 | 0.84 | HTT (0.68) | HTTMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL10812457 | 0.84 | TSHR (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL8586434 | 0.84 | ALDH1A1 (0.67) | HTTMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL4415350 | 0.84 | HTT (0.75) | HTTMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL9574717 | 0.82 | HTT (0.73) | HTTMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL340937 | 0.80 | HTT (0.69) | HTTMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL29687865 | 0.79 | ALDH1A1 (0.65) | HTTMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL4221058 | 0.78 | HTR1A (0.56) | MAPK1TDP1L3MBTL1KDM4E | |
| SCHEMBL14430331 | 0.77 | HTT (0.66) | HTTMEN1KMT2ASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190861-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | XENOPORT, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-1751087-B1 | LEVODOPA DERIVATIVES, AND COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8163958-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110201817-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7956212-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7534813-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7342131-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1751087-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005121069-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | WILSHIRE PHARMACEUTICALS, INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201817-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | HTT 648/4885MEN1 1821/4885KMT2A 1568/4885 |
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | HTT 648/4885MEN1 1821/4885KMT2A 1568/4885 |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | HTT 648/4885MEN1 1821/4885KMT2A 1568/4885 |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | HTT 648/4885MEN1 1821/4885KMT2A 1568/4885 |
| US-20120190861-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | COMT, DDT, DDC | HTT 648/4885MEN1 1821/4885KMT2A 1568/4885 |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | HTT 648/4885MEN1 1821/4885KMT2A 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.